Marty Makary, the Commissioner of the U.S. Food and Drug Administration (FDA), is set to depart the Trump administration following the president’s approval of a plan to remove him from the post, according to three sources familiar with the matter.
The move comes after months of escalating friction between Makary and the White House, as well as sustained pressure from powerful external interest groups. The departure leaves the administration facing a critical leadership void at a time when the Department of Health and Human Services (HHS) is already struggling with several high-profile vacancies in its top tiers.
Makary, a surgeon and author who took the helm in March 2025 with a mandate to streamline the approval of vaccines and medical devices, found his tenure defined by a series of high-stakes regulatory clashes. While he initially sought to modernize the agency’s pace, he ultimately became a flashpoint for conflict between the administration’s political goals and the FDA’s regulatory frameworks.
A Pattern of Friction: Vaping and Political Pressure
The catalyst for Makary’s exit appears to be a combination of internal mismanagement and direct policy disagreements with President Trump. Central to this was a heated dispute over the regulation of flavored electronic cigarettes. Makary had reportedly resisted internal efforts to approve the sale of fruit-flavored vapes, a stance that led to a direct and pointed confrontation with the president.
According to sources, the tension reached a breaking point recently, prompting the FDA to abruptly reverse its posture on flavored e-cigarettes just last week. This reversal highlighted a growing trend of executive pressure overriding the agency’s previous regulatory stances.
Beyond the vaping controversy, Makary faced intense scrutiny from the pharmaceutical industry and social conservatives. While he promised to accelerate drug approvals, several pharmaceutical companies expressed frustration with his handling of the process, claiming the “streamlining” had not materialized as promised.
The Mifepristone Conflict
One of the most potent drivers of Makary’s removal was his perceived inaction on the regulation of mifepristone, the medication used in most medical abortions. The administration’s pro-life allies, including Susan B. Anthony Pro-Life America, had been lobbying the FDA to reverse regulations that allow the drug to be sent via mail.
Because the FDA sets the national standards for how the drug is prescribed, any change in policy would have immediate, nationwide repercussions on abortion access. With medication abortions now accounting for approximately two-thirds of all abortions in the U.S., the issue has become a primary mobilization tool for conservative voters ahead of the midterm elections.
Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, had publicly called for Makary’s immediate firing, describing his approach as “indifference” that was “unacceptable” to pro-life voters.
Dividing the ‘Make America Healthy Again’ Coalition
Makary’s leadership also created a rift within the “Make America Healthy Again” (MAHA) movement led by HHS Secretary Robert F. Kennedy Jr. The coalition, while united in its desire to overhaul U.S. Health policy, found itself split over Makary’s priorities.
- The Critics: Vaccine skeptics within the MAHA wing lamented that Makary failed to remove COVID-19 vaccines from the market.
- The Supporters: Food policy advocates praised Makary for his efforts to eliminate artificial dyes from the food supply and his crackdown on ultra-processed foods.
This internal division left Makary without a stable political base within his own department, making him vulnerable to the “faction of officials” in the White House and HHS who viewed the FDA under his leadership as a site of “constant chaos” and policy confusion.
A Growing Leadership Vacuum in Public Health
The removal of the FDA Commissioner exacerbates a systemic leadership crisis within the U.S. Public health apparatus. The administration currently lacks permanent leadership in three of its most critical health roles.
| Agency/Role | Current Status | Impact |
|---|---|---|
| FDA Commissioner | Vacant (Pending Exit) | Instability in drug/food regulation |
| CDC Director | Vacant (Permanent) | Lack of steady disease surveillance lead |
| Surgeon General | Vacant (Permanent) | Absence of the nation’s chief medical voice |
Some White House advisors warned that firing another top health official could be a political miscalculation, potentially alienating the MAHA base. However, others argued that a leadership reset was inevitable and necessary to repair relationships with the pharmaceutical industry and the anti-abortion movement before November.
The timing of the exit was particularly abrupt. Makary was scheduled to testify before the Senate Appropriations Committee regarding the FDA’s proposed budget just one day after the plan for his removal was approved.
Disclaimer: This report discusses regulatory policies involving medications and public health. For medical advice or legal information regarding medication access, please consult a licensed healthcare provider or legal professional.
The administration is now expected to evaluate a broader restructuring of the FDA’s senior management to ensure better alignment with White House priorities. The next critical checkpoint will be the administration’s announcement of a nominee for the FDA Commissioner role, which will require Senate confirmation during a compressed legislative window before the midterms.
We want to hear from you. Do you believe political appointments should dictate regulatory science, or should the FDA remain insulated from White House pressure? Share your thoughts in the comments below.
